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The T cell Ig and mucin domain 3 (Tim-3) receptor has been implicated as a negative regulator of adaptive
immune responses. We have utilized a proteomic strategy to identify novel proteins associated with graft
versus host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT). Mass spectrometry
analysis of plasma from subjects with mid-gut and upper-gut GVHD compared with those without GVHD
identiﬁed increased levels of a protein identiﬁed with high conﬁdence as Tim-3. A follow-up validation study
using an immunoassay to measure Tim-3 levels in individual plasma samples from 127 patients demon-
strated signiﬁcantly higher plasma Tim-3 concentrations in patients with the more severe mid-gut GVHD,
compared with those with upper-gut GVHD (P ¼ .005), patients without GVHD (P ¼ .002), and normal
controls (P < .0001). Surface expression of Tim-3 was increased on CD8þ T cells from patients with grade 2 to
4 acute GVHD (P ¼ .01). Mass spectrometryebased proﬁling of plasma from multiple subjects diagnosed with
common diseases provided evidence for restricted release of soluble Tim-3 in the context of GVHD. These
ﬁndings have mechanistic implications for the development of novel strategies for targeting the Tim-3
immune regulatory pathway as an approach to improving control of GVHD.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
T cell Ig and mucin domain 3 (Tim-3) is a type-1 trans-
membrane receptor with immunoregulatory properties that
suppresses the activation of T helper 1 (TH1) cells on
engagement with ligand. Tim-3 is selectively expressed on
activated T cells and constitutively expressed on dendritic
cells (DCs) and natural killer (NK) cells [1]. Activation of Tim-
3 via ligand binding results in decreased T cell proliferation,
decreased T cell-mediated cytotoxicity, decreased IFN-g
production, and induction of apoptosis [2-5]. There is also
evidence that Tim-3 suppresses antitumor DCs [6]. Interac-
tions between Tim-3 and its ligand galectin-9 (gal-9) are
known to play a signiﬁcant regulatory role in autoimmune
disorders, chronic infection, tumor immunity, and trans-
plantation [4-11]. The binding of Tim-3 to gal-9 on activated
T cells induces apoptosis and/or blocks T cell effector func-
tions; however, interfering with the interaction between
Tim-3 and gal-9 in experimental models can exacerbate
acute inﬂammation [4,12]. The overall mechanisms and
pathways by which Tim-3 signals remain unclear.
Acute graft-versus-host disease (GVHD) in experimental
models can be modulated and prevented by interventions
that facilitate immune regulation. GVHD after allogeneic
hematopoietic cell transplantation in humans is a major
cause of morbidity and mortality, but clinically signiﬁcant
grades 2 to 4 disease do not occur in all recipients. Thedgments on page 1329.
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13.06.011frequency of grade 2 to 4 acute GVHD at our center is 71%,
and 14% of all patients develop severe grades 3 to 4 disease
[13]. Acute GVHD can cause inﬂammation and injury in the
skin, liver, and gastrointestinal mucosa. Acute GVHD of the
upper gut causes anorexia, nausea, and vomiting, sometimes
accompanied by mild diarrhea and rash, whereas acute
GVHD of the mid-gut causes more severe manifestations and
is associated with high-volume, protein-losing diarrhea
accompanied by abdominal pain and ileus. Upper-gut GVHD
can usually be controlled with lower doses of glucocorti-
coids, including topically active formulations [14,15]. In
contrast, mid-gut GVHD usually requires treatment with
higher initial glucocorticoid doses, may not respond to initial
treatment, and is associated with a higher risk of nonrelapse
mortality related to more intense immune suppression and
lack of response to treatment [16,17]. In the current era,
mortality in patients with acute GVHD is correlated with the
severity of gastrointestinal involvement, and liver and skin
involvement now play relatively minor roles in affecting
outcome [18,19].
Previous clinical studies have identiﬁed several plasma
cytokines and other proteins associatedwith Tcell activation,
inﬂammation, apoptosis, and tissue injury that are elevated
in patients with acute GVHD of skin, liver, and gut including
IFNg, IL-1b, IL-2, IL-2Ra, IL-6, IL-8, IL-12, IL-18, ST2, TNFa,
TNFRI, cytokeratin fragment 18 (KRT18), hepatic growth
factor (HGF), elaﬁn, and regenerating islet-derived 3-alpha
(REG3a) [20-30]. Elaﬁn, a product of keratinocytes, was
associated speciﬁcally with skin GVHD, and REG3a, a product
of Paneth cells, was associated with GVHD of the gut and
liver. Paneth cells residing at the bottom of epithelial cryptsTransplantation.
Table 1A
Patient and Transplantation Characteristics
Cohort 1, n ¼ 127
Discovery Samples, n ¼ 20 Validation Samples, n ¼ 127 Cohort 2, n ¼ 22
Upper-gut
GVHD, n ¼ 5
Mid-gut
GVHD, n ¼ 5
GVHDe n ¼ 10 GVHDþ n ¼ 78 GVHDe n ¼ 49 GVHDþ n ¼ 14 GVHDe n ¼ 8
Patient age, median (range), yr 42 (18 to 48) 49 (22 to 59) 39 (37 to 58) 43 (18 to 67) 45 (19 to 65) 45 (28 to 62) 39 (30 to 58)
Diagnosis
Acute leukemia 2 4 6 40 19 9 3
MDS 2 1 2 17 14 1 4
Lymphoma 0 0 0 7 4 1 1
Chronic leukemia (CLL, CML) 1 0 2 13 11 3 0
Other 0 0 0 1 1 0 0
Donor type
Related 3 2 7 33 31 5 3
Unrelated 2 3 3 45 18 9 5
Sex match
Female to male/Other 2/3 4/1 2/8 18/60 15/34 3/11 1/7
Graft type
Marrow/Blood/Cord 0/5 0/5 1/9/0 6/72/0 3/46/0 2/12/0 2/5/1
Conditioning regimen
Myeloablative 5 5 10 77 48 7 5
TBI >1000 cGy 1 3 4 32 9 7 3
Reduced intensity 0 0 0 1 1 7 3
CMV seropositive
Patient/Donor 3/1 4/2 2/1 41/31 18/16 9/6 3/1
GVHD prophylaxis
CNI þ MTX 4 5 9 72 44 10 7
CNI þ MMF 1 0 1 4 2 1 1
CNI þ MTX þ Sirolimus 0 0 0 2 3 2 0
CNI þ MTX þ Campath 0 0 0 0 0 1 0
Acute GVHD onset,
median (range), d
36 (23 to 43) 43 (23 to 52) NA 27 (7 to 64) NA 31 (16 to 65) NA
Acute GVHD
Grade 0 0 0 10 0 49 0 7
Grade 1 0 0 0 0 0 0 1
Grade 2 4 0 0 63 0 10 0
Grade 3 1 5 0 13 0 3 0
Grade 4 0 0 0 2 0 1 0
Organ-speciﬁc acute GVHD*
Mid-gut 0 5 0 15 0 3 0
Upper-gut 5 0 0 63 0 10 0
Skin only 0 0 0 0 0 1 0
Liver only 0 0 0 0 0 0 0
GVHD indicates graft-versus-host disease; CLL, chronic lymphocytic leukemia; CML, chronic myelogenous leukemia; MDS, myelodysplastic syndrome; TBI, total
body irradiation; CNI, calcinuerin inhibitor; MTX, methotrexate.
* Grade 2 to 4 acute GVHD.
Table 1B
Concurrent Involvement of Skin, Liver, and Gut GVHD
Clinically Signiﬁcant Grade 2 to 4 Acute GVHD
Skin
Only
Liver
Only
Gut
Only
Gut/
Skin
Gut/
Liver
Gut/Liver/
Skin
GVHDþ cohort 1 0 0 43 17 7 11
GVHDþ cohort 2 1 0 5 5 1 2
GVHDþ discovery
samples*
0 0 2 4 2 2
GVHD indicates graft-versus-host disease.
* Cohort 1 GVHDþ cases selected for the initial pooled plasma discovery
analysis.
J.A. Hansen et al. / Biol Blood Marrow Transplant 19 (2013) 1323e13301324of small intestinal mucosa secrete alpha-defensins (an
important part of the gut mucosal barrier’s antibacterial
defense) and interact with epithelial stem cells to regulate
proliferation [31,32]. KRT18 is released by apoptotic epithe-
lial cells and has been correlated with response to GVHD
treatment [33]. HGF, KRT18, and REG3a levels have been
compared in a common cohort of HCT recipients, and all 3
were conﬁrmed to be signiﬁcantly associated with lower-gut
and liver GVHD [34]. As a class, this last group of 4 plasma
proteins, elaﬁn, HGF, KRT18, and REG3a, represent markers
of tissue injury.
We have undertaken comprehensive proteomic proﬁling
of plasmas to identify potential markers of GVHD. We here
report identiﬁcation of novel form of TIM-3 represented by
release of the extracellular domain into the circulation in
association with acute GVHD at the presymptomatic stage.
This ﬁnding was validated by immunoassays of individual
samples from a large cohort of patients. We also show that
Tim-3 is up-regulated on T cells during acute GVHD, consis-
tent with murine models of GVHD and previous studies
demonstrating expression of Tim-3 on activated Th1 effector
cells, DC, and NK cells. The unexpected ﬁnding of elevated
plasma Tim-3 in GVHD patients in the current study suggeststhat soluble Tim-3, by interfering with the immune regula-
tory activity of Tim-3 expressed on effector T cells, may play
a signiﬁcant role in the pathogenesis of clinical GVHD.MATERIALS AND METHODS
Study Population
All patients received a myeloablative conditioning regimen followed by
infusion of hematopoietic cells from an HLA-matched related or unrelated
donor on day 0 (Table 1). Myeloablative conditioning regimens generally
contained high-dose cyclophosphamide with busulfan or 12 Gy to 13.2 Gy
Table 2
Ratio of Soluble Tim-3 in Pooled Case and Case-Control Plasma Samples*
Plasma Sample Upper Gut Mid-Gut
Ratio (P)* Day (range)y Ratio (P)* Day (range)y
Closest to GVHD
symptom onset
2.58 (.0489) 6 (2 to 7) 4.32 (<.0001) 6 (2 to 7)
Earlier before
onset
1.02 (ns) 10 (8 to 3) 3.19 (<.0001) 10 (8 to 14)
GVHD indicates graft-versus-host disease.
* Ratio of soluble Tim-3 in pooled case samples compared with control
samples determined by mass spectometry. P value represents cumulative
differences in labeled peptide intensities between cases and controls based
on t-test.
y Median day (range) of sample collection before onset of grades 2 to 4
acute GVHD.
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methotrexate to prevent GVHD. Prophylaxis for infections included
low-dose acyclovir, trimethoprim and sulfamethoxazole, or dapsone, an
antifungal agent, pre-emptive therapy with ganciclovir for patients with
cytomegalovirus (CMV) antigenemia or DNAemia, and antibiotics for
patients with neutropenia. Ursodiol was given as prophylaxis against
cholestasis [35].
Study Design
Patients were recruited before transplantation, and blood samples were
collected and cryopreserved weekly from day 7 through day 35, on days 56
and 80, and at the onset of acute GVHD. Patients who developed clinically
signiﬁcant grades 2 to 4 acute GVHD were declared cases, whereas patients
with grades 0 or 1 acute GVHD were declared case-controls. The study was
conducted in 3 phases as follows: (1) an initial discovery phase testing
pooled plasma samples bymass spectometry; (2) a clinical correlation phase
using Luminex-based immunoassays measuring (Luminex Model 200,
Luminex Corp., Austin, Tx) Tim-3 in the plasma of individual patients; and
(3) an immunophenotype analysis of Tim-3 expression by peripheral blood
mononuclear cell (PBMC). The discovery and clinical correlation phases
included 127 patients (cohort 1), and the immunophenotype analysis was
performedwith an independent cohort of 22 patients (cohort 2). The clinical
characteristics of cohort 1 and cohort 2 patients are summarized in Table 1.
In studies from both cohorts, only plasma and PBMC from GVHD cases
collected before beginning immunosuppression therapy were analyzed,
whereas samples from case-control patients without clinically signiﬁcant
acute GVHD were matched with cases for time from transplantation.
Patients in both cohorts gave informed consent under protocols approved by
the Fred Hutchinson Cancer Research Center Institutional Review Board.
Acute Gastrointestinal GVHD
The peak stage of gastrointestinal GVHD, the peak grade of GVHD, and
the date of onset of clinical signs and symptoms were independently scored
by P.J.M., according to the extent of rash, total serum bilirubin, the presence
of upper gastrointestinal symptoms, and daily stool volume [36]. Patients
were classiﬁed as (1) postallograft controls, with no evidence of acute GVHD
in the gut or liver at any time through day 100; (2) mid-gut gastrointestinal
GVHD (gut stage 2 to 4; that is, peak diarrhea volumes >1 liter per day or
severe abdominal pain); and (3) less severe GVHD, consisting mostly of
upper-gut gastrointestinal GVHD (gut stage 1; that is, anorexia, nausea,
vomiting, or early satiety with mucosal biopsy positive for GVHD [37] and, if
diarrhea was present, peak diarrhea volumes were <1 liter per day.
Collection and Processing of Blood Samples
Patients in cohort 1 had blood samples collected from central venous
access catheters into sodium ﬂuoride/potassium oxalate vacutainer and
maintained on ice until centrifugation. Plasma was aliquoted in .5 mL tubes
for cryopreservation at 80 degrees centigrade within 2 hours of phle-
botomy. Patients in cohort 2 had blood samples collected into heparinized
tubes; PBMC were isolated by Ficoll-hypaque density centrifugation,
resuspended in 10% DMSO and 90% FBS, and cryopreserved in liquid
nitrogen. Plasma was collected from blood samples obtained via veni-
puncture from 48 healthy consenting normal adults who were free of fever
or any respiratory or inﬂuenza-like symptoms for at least 7 days before
phlebotomy, and who had received no nonsteroidal anti-inﬂammatory
drugs, glucocorticoid medication, or antibiotics for at least 48 hours. This
normal control cohort included 29women and 19men, with amedian age of
37 years (range, 23 to 67 years).Discovery PhasedQuantitative Proﬁling of Plasma Samples by Mass
Spectrometry
A subset of 20 patients from cohort 1 was selected for in-depth pro-
teomic analysis of plasma specimens and consisted of 5 patients with upper-
gut GVHD, 5 with mid-gut GVHD, and 10 allograft-matched case-control
patients without clinically signiﬁcant acute GVHD, whose plasma samples
had been collected at the same time point after transplantation as samples
from patients with upper-gut and mid-gut GVHD, respectively. From each of
these patient groups, 100 mL of plasma was removed from thawed aliquots
and pooled in a single ampoule, yielding pooled specimens from patients
with upper-gut and mid-gut GVHD and their respective allograft case-
controls without GVHD. Four independent large-scale quantitative proteo-
mics experiments were performed using a previously described method [7]
that employed immunodepletion, isotopic labeling with acrylamide [38],
extensive fractionation [39], and high-resolution tandem mass spectrom-
etry. Each experiment compared a 300 mL pool of plasma from 5 upper- or
mid-gut cases with a 300 mL pool of 5 controls (equal volume). Pools of case
and control plasma samples were immunodepleted of the top 6 most
abundant proteins (albumin, IgG, IgA, transferrin, haptoglobin, and anti-
trypsin) using a Hu-6 column (4.6  250 mm, Agilent Technologies, Santa
Clara, California). Columns were equilibrated with buffer A at .5 mL/min for
13 minutes, and pooled plasma samples were injected after ﬁltration
through a .22 mm syringe ﬁlter. Flow-through fractions were collected for
10 minutes at a ﬂow rate of .5 mL/min buffer A, and stored at 80C until
further use. Immunodepleted samples were concentrated using a Centricon
YM-3 device (Millipore Corporation, Billerica, MA) and rediluted in 8M urea,
30 mM Tris, pH 8.5, .5% OG (octyl-beta-d-glucopyranoside, Roche Diagnos-
tics). Samples were reduced with DTT and isotopic labeling of cysteine
residues of intact proteins was performed. Pools received either the light
acrylamide isotope (C12, Sigma-Aldrich) or the heavy 1,2,3-C13-acrylamide
isotope (C13, Cambridge Isotope Laboratories). Alkylation with acrylamide
was performed for 1 hour at room temperature. For each of the 4 experi-
ments, a case pool was then mixed with a corresponding control pool for
further analysis.
In each experiment, the combined isotopically labeled case-control
samples were separated by an automated online 2D HPLC system (Shi-
madzu). The combined labeled plasma samples were separated in the ﬁrst
dimension by anion exchange chromatography (Poros HQ/10, 10 x 100 mm,
Applied Biosystems) using an 8-step elution (0 to 1000 mM NaCl) at .8 mL/
min. Fractions from each of the 8 anion-exchange separation elution steps
were automatically transferred onto a reversed-phase column (PorosR2/10,
4.6  100 mm, Applied Biosystems) for a second dimension of separation. A
25-minute gradient elution (5% to 95% mobile phase B) was used at 2.4 mL/
min. Mobile phase A for anion-exchange chromatography consisted of
20mM Tris (Sigma-Aldrich), 6% isopropanol (Fisher Scientiﬁc), and 4M urea,
pH 8.5, and mobile phase B was the same composition and pH as mobile
phase A with 1 M NaCl (Fisher Scientiﬁc) added. Mobile phase A for
reversed-phase chromatography consisted of 95% water, 5% acetonitrile, and
.1% TFA (Supelco), and mobile phase B consisted of 90% acetonitrile, 10%
water, and .1% TFA. In-solution digestion was performed with lyophilized
aliquots from the reversed-phase (second dimension) fractionation step.
Proteins were resuspended in .25 M urea containing 50 mM ammonium
bicarbonate and 4% acetonitirle and then digested overnight at 37C with
modiﬁed trypsin (Promega). The digestion was stopped by addition of 10%
formic acid. Aliquots were subjected tomass spectrometry shotgun analysis.
Ninety-six fractions were analyzed for each experiment using an LTQ-
Orbitrap (Thermo) mass spectrometer coupled with a NanoLC-1D (Eksi-
gent). Liquid chromatography separationwas performed on a 25-cm column
(Picofrit 75 mm i.d., New Objectives, packed in-house with Magic C18 resin)
using a 90-minute linear gradient from 5% to 40% of acetonitirle in .1% formic
acid at 300 nL/min for shotgun analysis. Spectra were acquired in data-
dependent mode over m/z range 400 to 1800, and included selection of
the 5 most abundant doubly or triply charged ions of each MS spectrum for
MS/MS analysis. Mass spectrometer parameters included capillary voltage
of 2.0 kV, capillary temperature of 200C, resolution of 60,000, and target
value of 1,000,000.
Analysis of Mass Spectrometry Discovery Data
Mass spectra were searched using Mascot against the human Interna-
tional Protein Index (IPI) database (v. 3.13). Quantitative information was
extracted from acrylamide labeled peptides using an in-house script (Q3) for
peptides with minimum PeptideProphet ¼ .75, expect score <.10, and
maximum fractional delta mass ¼ 20 ppm [38]. Also, because the label
orientationwas reversed in some experiments, we additionally required that
any quantiﬁed peptide had to be observed in both isotopic states at least once
in at least 1 experiment. This criterion removes spurious ratios that arise
because of misidentiﬁcation. Proteins with ProteinProphet scores>.90 were
aligned by their protein group number to identify master groups of indis-
tinguishable proteins. The master group ratio for each experiment was set to
Figure 1. Levels of Tim-3 in pg/mL were measured in 185 individual plasma
samples. These included 78 samples from cohort 1 cases with mid-gut (n ¼ 15)
or upper-gut (n ¼ 63) acute GVHD, 59 individual plasma samples from 37
case-controls matched with cases for time post-transplant, and 48 samples
from normal healthy controls. Boxes represent 25th, 50th, and 75th percen-
tiles; whiskers indicate 5th and 95th percentiles.
Table 3
Multivariate Analysis of Clinical Variables Associated with Soluble Tim-3
Plasma Levels*
Characteristic Effect Ratio (95% CI) P Value
Sample characteristics
Upper-gut GVHDy 1.04 (.80 to 1.33) .78
Mid-gut GVHDy 1.98 (1.20 to 3.29) .008
Patient pretransplantation characteristics
CMV seropositive pretransplantation 1.32 (1.02 to 1.72) .04
Donor CMV seropositive 1.17 (.92 to 1.50) .21
Unrelated donor 1.35 (1.02 to 1.78) .04
Mismatched donor 1.09 (.76 to 1.57) .63
Age (per decade) 1.00 (.98 to 1.03) .75
Female .94 (.72 to 1.23) .66
Female to male D/R .86 (.62 to 1.20) .37
PBSC .93 (.56 to 1.56) .79
TBI (>1200 cGy) 1.14 (.88 to 1.47) .33
GVHD indicates graft-versus-host disease; CMV, cytomegalovirus; PBSC,
peripheral blood stem cells; TBI, total body irradiation; D/R, donor/recipient.
* Multivariate analysis of soluble Tim-3 plasma levels in 303 samples
collected from 127 patients before initiation of treatment for acute GVHD.
Data were analyzed after log transformation of Tim-3 levels. The “effect
ratio” is the antilog of the estimated difference in means on the log scale,
and represents a multiplicative effect of covariates on Tim-3 levels. Models
were also adjusted for time since HCT (linear, quadratic, and cubic terms).
y Deﬁned as any sample within 15 days of onset of treatment for GVHD
and compared with grade 0 to 1 acute GVHD.
Table 4
Transplantation Characteristics Associated with Tim-3 Cellular Expression*
Clinical Variables CD3þ
T cells
CD4þ
T cells
CD8þ
T cells
CD19þ
B cells
CD56þ
NK cells
Age, patienty .58 .90 .83 .60 P ¼ .002
CMV serostatus,
patientz
P ¼ .01 P ¼ .01 .30 P ¼ .02 .83
* Univariate associations of the percentage of Tim-3þ blood mononuclear
cells in GVHDþ cases and GVHDe case-controls studied during the ﬁrst
100 days after allogeneic HCT (P values and direction of association). Study
includes 22 HCT patients (14 acute GVHDþ cases and 8 GVHDe case-
controls) and 61 patient samples (32 cases and 29 case-controls). Samples
from case and case-control patients were matched for time post trans-
plantation: median 30 (range, 20 to 55) days and 32 (range, 25 to 36) days,
respectively (P ¼ .97). No signiﬁcant effect was observed for sex, sex match,
donor type (related, unrelated), HLA match, donor CMV serostatus, HSC
source (blood, marrow), and TBI >1000 cGy.
y Increasing patient age by decade.
z CMV serostatus (positive patient, negative donor) pretransplantation.
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rithmically transformed and median centered. Proteins that had become
defunct in IPI or were immunodepleted were removed from the analysis.
Mean log2 ratios and moderated P values for groups of experiments were
computed using the LIMMA package from bioconductor.org and weighted
using the number of quantitated events (peptides) [40].
Clinical Correlation PhasedLuminex Microbead Assay
A sandwich ELISA method was used to screen commercially available
capture/detection matched pair antibodies to develop optimal assay char-
acteristics for quantitation of human Tim-3 in plasma from patients in
cohort 1. Recombinant human Tim-3:Fc chimera (R&D Systems #2365-TM,
Minneapolis, MN) at a concentration of 100 ng/mL was used as a positive
control for testing various capture/detection antibody combinations. Our
optimal ELISA used an afﬁnity-puriﬁedmonoclonal capture antibody against
human Tim-3 (R&D Systems #MAB2365) and a biotinylated polyclonal
detection antibody (R&D Systems #BAF2365). We next conjugated this
capture antibody to Luminex microbeads (BioRad, Hercules, CA) and tested
the operating characteristics of the microbead assay using the recombinant
human Tim-3:Fc spiked into assay buffer at 100 ng/mL as the high standard
and diluted serially to .1 pg/mL.
Clinical Correlation PhasedImmunophenotyping and Flow Cytometry
Cryopreserved PBMC from cohort 2 patients were thawed and subjected
to cell surface staining using ﬂuorochrome-labeled anti-human monoclonal
antibodies CD3 FITC, CD8b APC, CD4 APC-Cy7 (BD Biosciences, Franklin
Lakes, NJ), Tim-3 PE, CD19 PerCP-Cy5.5, CD56 PE-Cy7, and CD14 Paciﬁc Blue
(Biolegend, San Diego, CA). Isotype control antibodies included IgG1k FITC,
IgG1k PE, IgG1k PerCP-Cy5.5, IgG1k PE-Cy7, IgG1k APC-Cy7 (BD Biosci-
ences), and IgG2ak APC and IgG1k Paciﬁc Blue (Biolegend). Flow cytometry
data were collected on a BD LSRII (BD Biosciences) and analyzed using
CellQuest Pro (BD Biosciences) software.
Statistical Analyses
All Tim-3 levels were log transformed for statistical analysis. For the
presentation in Figure 1, the sample most proximal to onset of GVHD
treatment was used for GVHD cases. For mid-gut cases, the median day of
this sample was day -3 (range, 15 to 0) before GVHD clinical onset; for
upper-gut cases the median day of this sample was day -2 (range, 10 to 1)
before onset. Thirteen mid-gut cases and 46 upper-gut cases were time-
matched to a no-GVHD control sample. Case and control groups were
compared by paired t-test. Mid-gut cases and upper-gut cases, and GVHD
cases and normals were compared by 2-sample t-test. The multivariate
analysis in Table 3 includes all 303 samples from 127 cases and controls.
Generalized estimating equation methods using an exchangeable correla-
tion structure were used to account for varying numbers of samples per
subject. GVHD samples were deﬁned as any sample taken within 15 days
before the onset of treatment for GVHD. Models were also adjusted for time
since HCT, using linear, quadratic, and cubic terms. The regression effects on
the log scale were transformed by antilog to effect ratios, which represent
multiplicative effects of covariates on Tim-3 plasma levels. Tim-3 cellularexpression in Table 4 was also analyzed by generalized estimating equation
methods using exchangeable correlation. Logistic regression was used to
perform a receiver-operating characteristic (ROC) analysis of Tim-3 as
a predictor of GVHD, using day 21  3 days post-transplantation as a land-
mark time. Samples from 64 patients without a history of acute GVHD were
available in this window; 7 subsequently developed mid-gut GVHD and
24 subsequently developed upper-gut GVHD. Percentages and absolute
numbers of cells expressing surface Tim-3 were compared by 2-sample
t-test using Satterwaite’s correction for unequal variance.RESULTS
Acute GVHD
Seventy-eight of the 127 patients in cohort 1 developed
clinically signiﬁcant grades 2 to 4 acute GVHD (grade 2,
n ¼ 63; grade 3, n ¼ 13; grade 4, n ¼ 2), and 49 patients had
no acute GVHD. Fifteen (19%) of the 78 hadmore severe mid-
gut GVHD; 63 (81%) had less severe upper-gut GVHD
(Table 1). The median day of onset of grades 2 to 4 acute
GVHD was day 26 (range, 7 to 64) after HCT. Fourteen (64%)
of the 22 patients in cohort 2 developed grades 2 to 4 acute
GVHD (grade 2, n ¼ 10; grade 3, n ¼ 3; grade 4, n ¼ 1).
Aliquots of selected cohort 1 plasma samples collected at
100 101 102 103 104
Figure 2. FACS histogram for expression of Tim-3 on gated CD8þ T cells from
a patient with clinically signiﬁcant acute GVHD (PT no. 0728). The shaded area
represents the staining proﬁle for an isotype-negative control antibody, and
the horizontal line represents the gating used to deﬁne positive expression of
Tim-3 (57.5%). The x-axis represents ﬂuorescent intensity and the y-axis
represent number of events.
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One pool included samples collected from 5 patients at
a median of 2 days (range, 1 to 3) before the onset of upper-
gut GVHD, and the other pool included samples collected
from 5 patients at a median of 6 days (range, 2 to 7) before
the onset of mid-gut GVHD. Similarly, aliquots of selected
cohort 1 plasma samples collected 1 to 2 weeks before the
clinical onset of GVHD were pooled. One pool included
samples collected from 5 patients at a median of 10 days
(range, 8 to 13) before the onset of upper-gut GVHD, and the
other pool included samples collected from 5 patients at
a median of 10 days (range, 8 to 14) before the onset of mid-
gut GVHD.
Discovery of Elevated Tim-3 Levels in Acute Gut GVHD
Mass spectrometry identiﬁed several tryptic peptides
spanning from amino acids 56 to 142 in the extracellular
domain of Tim-3. Quantitative data derived from a cysteine-
containing peptide spanning amino acids 56 to 69 yielded
increased ratios in pooled plasma samples from patients
before the onset of acute gut GVHD compared with case
matched controls, based on differential isotopic labeling.
Tim-3 plasma levels were higher in patients with mid-gut
compared with upper-gut GVHD, and higher in the samples
collected closest to GVHD onset compared with samples
collected earlier (Table 2). The Tim-3 case/control ratios in
pooled mid-gut samples closest to GVHD onset and earlier
were 4.32 and 3.19 (P < .0001), respectively. The Tim-3 case/
control ratios in pooled upper-gut samples closest to GVHD
onset and earlier were 2.58 (P ¼ .05) and 1.02 (P ¼ not
signiﬁcant), respectively. In separate studies, we have per-
formed in-depth quantitative plasma proteome proﬁling of
samples collected from subjects who were diagnosed with
lung, colon, and breast cancer and subjects who were diag-
nosed with coronary heart disease and stroke. None of these
samples yielded increased levels of circulating TIM-3 (data
not shown), suggestive of restricted release of soluble TIM-3
in the context of GVHD.
Validation of Plasma Tim-3 Association with Acute GVHD
by Immunoassay
Tim-3 levels were measured by immunoassay in 185
individual plasma samples selected for validation testing.
These included samples from 78 cohort 1 cases with clini-
cally signiﬁcant GVHD, 59 samples from 37 GVHDecase-
controls, and 48 samples from normal healthy controls.
Signiﬁcantly higher Tim-3 levels were found in plasma of
patients with acute gastrointestinal GVHD characterized by
more severe mid-gut involvement (median 11,550 pg/mL)
compared with (1) patients with the less severe GVHD
characterized mostly by upper-gut involvement (median,
4670 pg/mL; P ¼ .005); and (2) time-matched case-controls
(median, 2710 pg/mL; P ¼ .002) (Figure 1). Plasma levels of
Tim-3 were also higher in the samples of less severe upper-
gut GVHD compared with their time-matched case-controls
(medians, 4670 versus 3460 pg/mL; P ¼ .03). Tim-3 plasma
levels were also signiﬁcantly higher in GVHD-free case-
control samples compared with normal healthy controls
(medians, 3275 versus 2285 pg/mL; P < .0001).
Clinical variables previously associated with risk of acute
GVHD were included in a multivariate analysis to determine
any association of these variables with Tim-3 plasma levels.
Donor type unrelated compared with related had an effect
ratio (ER) of 1.35 (P ¼ .04) and a positive CMV serology test
pretransplantation in the patient had an ER of 1.32 (P ¼ .04)(Table 3). The ER formid-gut GVHD in themultivariatemodel
was 1.98 (P ¼ .008), whereas the ER for upper-gut GVHD was
not statistically signiﬁcant (ER ¼ 1.04, P ¼ .78). Patient age,
donor CMV serostatus pretransplantation, HLA mismatch,
sex, a female donor for a male recipient, and blood as a stem
cell source had no statistically signiﬁcant association with
Tim-3 plasma levels in this model.
To further evaluate the effect of elevated Tim-3 levels on
risk of gut GVHD, we performed a ROC analysis using day
21  3 days posttransplantation as a landmark time and
identiﬁed 64 patients with samples collected in that window
(excluding samples obtained from patients after the onset of
GVHD). Seven of the 64 patients subsequently developed
mid-gut GVHD, 24 subsequently developed upper-gut GVHD,
and 33 did not develop GVHD. An ROC analysis of Tim-3
plasma levels as a predictor of any GVHD (n ¼ 31) versus
control (n ¼ 33) had an area under the ROC curve of .59, P ¼
.17. An ROC analysis of Tim-3 as a predictor of mid-gut GVHD
(n ¼ 7) versus all others (n ¼ 57) had an area under ROC
curve of .79, P ¼ .003. Because of the limited number of mid-
gut cases, it was not possible to performmultivariate analysis
accounting for other GVHD risk factors. Nonetheless, Tim-3
was the strongest univariate risk factor.
Expression of Tim-3 on Peripheral Blood Mononuclear
Cells of Patients with Acute GVHD
Further validation was undertaken with an independent
cohort of 22 patients (cohort 2). Fourteen of 22 patients
developed clinically signiﬁcant grades 2 to 4 acute GVHD
(grade 2, n ¼ 10; grade 3, n ¼ 3; grade 4, n ¼ 1), including 3
with mid-gut, 9 with upper-gut, and 2 with skin-only acute
GVHD (Table 1). The median GVHD onset was day 31 (range,
16 to 65) after transplantation. Blood samples from cases
were collected at a median of 4 (range, 0 to 10) days before
GVHD onset and at amedian of 30 (range, 20 to 55) days after
HCT. Blood samples from time-matched case-controls were
P < .001
P < .001
P =.08
P = .01
P = ns
P = ns
P = ns
P = .09
P = .07
P = .09
Figure 3. Tim-3 cell-surface expression measured as percentage (%) (Figure
3A) and absolute cell counts (Figure 3B) for Tim-3þ CD14þ monocytes, CD4þ
and CD8þ T cells, CD56þ natural killer cells and CD19þ B cells. Bar graphs
represent Tim-3 expression on cells from patients with clinically signiﬁcant
acute GVHD (GVHDþ, shaded black), patients who remained GVHD-free for at
least the ﬁrst 100 days posttransplant (GVHD -, shaded stripe) and cells from
healthy normal controls (NC, shaded yellow).
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Expression of Tim-3 on PBMC from cases was determined by
ﬂow cytometry and compared with case-controls. A repre-
sentative histogram illustrating Tim-3 expression on gated
CD8þCD3þ PBMC from a patient 2 days before the onset of
clinically signiﬁcant acute mid-gut GVHD is shown in
Figure 2.
The percentage of Tim-3þ/CD8þT cells in acute GVHD
cases was signiﬁcantly higher compared with case-controls
(38  5% versus 22  3%, P ¼ .01) (Figure 3A), and the
percentage of Tim-3þ/CD4þ T cells tended to be higher in
acute GVHD cases compared with case-controls, but with
only marginal (24  4% versus 15  3%, P ¼ .08). We also
found a nonsigniﬁcant trend for a higher percentage of Tim-
3þ/CD19þ B cells in acute GVHD cases compared with both
case-controls (21  6% versus 10  2%, P ¼ .11) and normal
healthy controls (216% versus 12 2%, P¼ .09). The results
showed a nonsigniﬁcant trend for higher absolute numbers
of Tim-3þ/CD8þ Tcells in cases compared with case-controls,
with no signiﬁcant difference in the absolute number of Tim-
3þ/CD4þ T cells and Tim-3þ/CD19þ B cells in cases compared
with case-controls (Figure 3B). No statistically signiﬁcant
differences were observed in the percentage or absolute
number of Tim-3þ/CD56þ NK cells in cases, case-controls,
and normal controls. The expression of Tim-3 on CD14þmonocytes was uniformly high in cases, case-controls, and
normal controls ranging between 94  2% and 98 .4% (data
not shown).
A univariate analysis of clinical variables that might affect
Tim-3 expression in cells was performed for patient age, sex,
sex mismatch, CMV pretransplantation serostatus, donor
type, HLA match, and use of high-dose TBI (>1000 cGy) in
the pretransplantation conditioning. Tim-3 expression on
CD4þ T cells and CD19þ B cells were signiﬁcantly higher in
CMV-seropositive patients (P ¼ .01 and P ¼ .02, respectively),
and Tim-3 expression on CD56þ NK cells was signiﬁcantly
higher in older patients (P ¼ .002) (Table 4).
DISCUSSION
The principal ﬁnding in this study was the discovery that
plasma levels of the soluble extracellular domain of Tim-3
were elevated in patients with clinically signiﬁcant acute
GVHD and that higher levels of Tim-3 were associated with
themore severemid-gut GVHD as compared with less severe
upper-gut GVHD and the absence of GVHD. The presence of
Tim-3 in these plasma samples was initially detected bymass
spectometry that identiﬁed several tryptic peptides corre-
sponding to the extracellular domain of Tim-3, a member of
the T cell Ig and mucin-domain (Tim) family of type I
glycoproteins. Themature Tim-3molecule consists of a distal
Ig variable region (IgV)-like extracellular domain, a proximal
mucin-like extracellular domain, a transmembrane region,
and an intracellular domain containing a tyrosine phos-
phorylation motif [41]. The full-length that underwent
translatation protein consists of 288 amino acids with an
extracellular domain of 171 amino acids.
After the discovery of soluble Tim-3 in pooled plasma
samples by mass spectrometry, validation of the Tim-3
association with acute GVHD was accomplished in a 2-step
process.
First, a microbead assay for TIM-3 was developed with
a dynamic range of 5 to 10,000 pg/mL, speciﬁc for TIM-3, and
with no detectable cross-reactivity with other analytes. TIM-
3 levels were then measured in 303 individual plasma
samples from all 127 cohort 1 patients. Signiﬁcantly
increased Tim-3 plasma levels were found in cohort 1 cases
with grades 2 to 4 acute GVHD overall, with signiﬁcantly
higher plasma levels found in patients with the more severe
mid-gut compared with upper-gut acute GVHD. In addition,
an ROC analysis of Tim-3 as a predictor of mid-gut GVHD
compared with all others had an area under ROC curve of .79
(P ¼ .003). In a second independent validation, staining for
Tim-3 expression on PBMC from an independent cohort of
patients demonstrated a signiﬁcantly higher percentage of
Tim-3þ/CD8þ Tcells in cases with clinically signiﬁcant grades
2 to 4 compared with case-controls with grades 0 to 1 acute
GVHD. We also observed trends for higher percentages of
Tim-3þ/CD4þ T cells and Tim-3þ/CD19þ B cells in patients
with GVHD compared with those without clinically signiﬁ-
cant GVHD. Tim-3 expression on T cells from normal healthy
controls was low, but Tim-3 expression on NK cells and
monocytes was high, both in patients overall and in normal
controls, as reported previously [42].
The mechanism by which Tim-3 is released from cells is
not known. The presence of soluble Tim-3 identiﬁed in the
plasma of these GVHD patients could represent an actively
secreted slice variant, a cleaved product, or the passive
release of a soluble fragment from apoptotic cells. Using PCR
primers for the full Tim-3 gene and putative splice variant,
Geng et al. found expression of the full Tim-3 transcript in
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splice variant was expressed only in splenocytes [43]. After
in vitro activation of splenocytes, expression of both the full-
length Tim-3 message and the splice variant were increased.
Supernates of transfected CHO cells were analyzed by
Western blots and a w24 kDa protein was identiﬁed that
bound anti-Tim-3 antibody. The size of the secreted protein
was consistent with the predicted size of the glycosylated
splice variant, demonstrating that the splice variant encodes
a soluble form of Tim-3 [43].
Expression of cellular Tim-3 is highly variable. Expression
on normal human blood T cells has been reported as low or
undetectable, but Tim-3 is constitutively expressed on cells
of the innate immune system including NK cells, monocytes,
and DC [5,42,44]. Hastings et al. found Tim-3 expression on
1% to 2% of CD8þ blood T cells, no detectable expression on
CD4þ blood T cells, but approximately 10% of CD4þ T cells in
human lymph node were Tim-3þ [5]. Studies in mice have
also found distinct differences in Tim-3 expression in adap-
tive and innate immune cells [8,45]. Low levels of Tim-3
expression, <5%, were found on CD4þ and CD8þ splenic
T cells. Tim-3 expression on activated CD4þ T cells was found
to be limited to the Th1 and Th17 subsets [5,46-49].
Previous studies have demonstrated that Tim-3 plays
a signiﬁcant role in regulation of the immune response,
autoimmunity, and transplantation including murine GVHD.
T cell receptor-mediated activation induces signiﬁcant
upregulation of Tim-3 expression in both CD4þ and CD8þ
T cells [46]. Human Tim-3eCD4þ T cells isolated from human
lymph node proliferate vigorously and secrete cytokines
when stimulated ex vivo with plate-bound anti-CD3/CD28
antibodies, but Tim-3þCD4þ T cells do not. Increased
production of IFNg, by stimulated Tim-3þCD4þ T cells occurs,
however, when Tim-3 blocking antibodies are added or
when Tim-3 expression is knocked down with siRNA [50].
Other experiments have demonstrated that the interaction of
Tim-3 with Gal-9 expressed on accessory cells suppresses
Th1 responses and facilitates the development of peripheral
tolerance, whereas T cell activation in Tim-3 KO (Tim-3/)
mice and in mice given a Tim-3 fusion protein, leads to
uncontrolled Th1 responses and resistance to peripheral
tolerance [4,48,49]. The administration of anti-Tim-3 anti-
body in an EAE induction model exacerbates the intensity of
disease. Defective expression of Tim-3 occurs in patients
with autoimmune disease, suggesting that dysfunction in the
Tim-3 immune regulatory pathway may result in persistent
autoimmune reactivity [50,51]. Ndhlovu et al. showed that
human NK cells transcribe the highest amounts of Tim-3
among all lymphocytes and in contrast to T cells Tim-3
expression by NK cells corresponds with functional matu-
ration [52]. Exposure of NK cells to Tim-3 antibodies,
however, suppresses NK cell-mediated cytotoxicity, indi-
cating that NK cells like T cells are subject to negative regu-
lation in the presence of Tim-3 ligand.
Studies by Oikawa et al. in a murine model of acute GVHD
found marked up-regulation of Tim-3 expression on splenic
and hepatic CD4þ and CD8þ T cells, dendritic cells, and
macrophages [8]. The most prominent increase was noted
among hepatic CD8þ T cells. Administration of anti-Tim-3
antibody increased the severity of acute GVHD, suggesting
that blocking the interaction between Tim-3 and its ligand
interfered with Tim-3emediated modulation of T cell
effector activity, resulting in a stronger and more pathogenic
GVHD reaction. These same investigators also used a Tim-3/
IgH fusion protein to demonstrate up-regulation of Tim-3ligand in splenic T cells, DCs, and macrophages, but not
hepatic lymphocytes during GVHD, suggesting that dysre-
gulation of the Tim-3 pathway in this model contributes to
severity of hepatic acute GVHD [8]. Veenstra et al. have
recently conﬁrmed and extended the ﬁndings of Oikawa
et al. in experiments using Tim-3/ donor T cells or a Tim-3-
Ig fusion protein in an H2-incompatible GVHD model [11].
The blocking or absence of Tim-3 increased lethality;
however, GVHD lethality was signiﬁcantly reduced in Gal-9
Tg recipients expressing the Tim-3 ligand Gal-9 in B220þ,
CD11 bþ, and CD11cþ splenic APC compared with wild-type
recipients. These Tim-3 fusion protein experiments suggest
that circulating Tim-3 can inhibit Tim-3 regulatory activity
and thereby allow unrestrained expansion of Th1 effector
cells, an increase in inﬂammation, and exacerbation of GVHD
[43,48,49]. Reduction of Tim-3 plasma concentrations, on the
other hand, might provide a therapeutic target for limiting
GVHD activity and promoting the development of tolerance.
In summary, concentrations of the soluble extracellular
domain of Tim-3 are increased in the blood of patients before
clinical onset of acute GVHD, and levels correlate with the
severity of gut GVHD. We speculate that plasma Tim-3 may
exacerbate the severity of acute GVHD by blocking the
interaction between Tim-3 and its ligand, thereby abrogating
the regulatory activity of the Tim-3 pathway. Mechanistic
studies are needed to better understand the biology of Tim-3
in the alloimmune reaction and to determine whether the
increased plasma concentrations of Tim-3 associated with
acute GVHD represent dysregulation of a pathway that,
under optimal conditions, canmitigate the inﬂammation and
tissue injury associated with acute GVHD. Better under-
standing of cellular Tim-3emediated immune regulation and
the possible proinﬂammatory effect of soluble Tim-3 may
provide the insight and rationale for novel therapies targeted
to enhance the ability of Tim-3 to down-regulate the effector
component of the alloimmune response and facilitate
induction of tolerance.
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